NCT05872204View on ClinicalTrials.gov

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Low Grade Serous Ovarian CarcinomaAdult Type Granulosa Cell Tumor
Interventions
DRUG

Abemaciclib

150 mg tablet twice daily

DRUG

Letrozole

2.5 mg tablet once daily

Trial Locations (12)

3000

RECRUITING

UZ Leuven, Leuven

4000

RECRUITING

CHU de Liège, Liège

9000

RECRUITING

UZ Gent, Ghent

31059

RECRUITING

Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse

33000

RECRUITING

Institut Bergonie, Bordeaux

44800

RECRUITING

Institut De Cancerologie De L'Ouest, Saint-Herblain

67200

RECRUITING

Institut De Cancerologie Strasbourg Europe, Strasbourg

69008

RECRUITING

Centre Leon Berard, Lyon

75020

RECRUITING

Groupe Hospitalier Diaconesses Croix Saint Simon, Paris

9713 GZ

NOT_YET_RECRUITING

University Medical Center Groningen, Groningen

3015 GD

RECRUITING

Erasmus Medical Center Rotterdam, Rotterdam

3584 CX

NOT_YET_RECRUITING

University Medical Center Utrecht, Utrecht

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER